SISVEL
27.5.2020 15:02:05 CEST | Business Wire | Press release
Sisvel International S.A. (“Sisvel”) today announced that Mitsubishi Electric Corporation (“Mitsubishi Electric”) has entered into a patent license agreement for both Sisvel’s VP9 and AV1 Licensing Programs.
“As a company with a long tradition in research and development in the video coding technologies, it goes without saying that we respect patent positions held by other innovators and that we take a license under the patents offered by Sisvel’s Video Coding Licensing Platform implemented in our products,” says Mr. Yoshimichi Shishido, Senior General manager of Corporate Licensing Division at Mitsubishi Electric.
“We have the utmost respect for Mitsubishi Electric’s position and welcome them as the first licensee of our patent pools. We believe this represents a strong signal to the market and we expect that other respectful implementers will follow Mitsubishi Electric’s example,” says Mattia Fogliacco, President of Sisvel International S.A..
Likewise, Sisvel has also granted a license to the Spanish company, Tremmen Tecnologica S.L. (“Tremmen Tecnologica”) for both the VP9 and AV1 Licensing Programs.
Mr. Javier Galiana, CEO of Tremmen Tecnologica, has declared: “Tremmen Tecnologica fully respects Intellectual Property Rights and we are pleased to have signed these license agreements with Sisvel. Sisvel is one of the most respected players in the licensing industry and these licenses will give Tremmen Tecnologica access to these important video codec technologies.”
Sisvel’s Video Coding Licensing Platform includes two, separately offered licensing programs for patents essential to the VP9 and AV1 video coding formats. The platform has a total of 14 patent owners (fourteen for the AV1 pool and twelve for the VP9 pool), including some of the world’s leading technology companies supporting media content. More information is available at: https://www.sisvel.com/licensing-programs/audio-and-video-coding-decoding/video-coding-platform/introduction .
“We are extremely pleased that we could group together this distinguished selection of patent owners and help them to create a fair return on their research and development investments, as well as allowing the market to easily access the technologies represented by the relevant patents,” Davide Ferri, Managing Director of Sisvel Technology Srl, concluded.
Further details on the terms and conditions of Sisvel’s Video Coding Licensing Platform are available at: https://www.sisvel.com/licensing-programs/audio-and-video-coding-decoding/video-coding-platform/license-terms or from Sisvel upon request by companies currently requiring a license.
About Sisvel
Sisvel International S.A. is the holding company of the Sisvel Group. Sisvel is a world leader in fostering innovation and managing IP. The group identifies, evaluates and maximises the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Sisvel has more than 35 years’ experience in the management of successful patent portfolios, including those relating to audio compression standards (MP3 and MPEG audio), as well as broadcasting and digital terrestrial television standards maintained by the Digital Video Broadcasting Project. Sisvel operates patent pools and joint licensing programmes in the fields of mobile communication, wireless local area networking 802.11, video coding, digital video broadcasting, recommendation engines and broadband access to data networks.
For additional information, please visit: www.sisvel.com .
Those interested in more information about the pools, please contact Sisvel at the following e-mail addresses: vp9@sisvel.com ; or av1@sisvel.com .
Background information on the history of video codecs and why it is important to sustain innovation is available at: www.playtherightfuture.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200527005106/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom